Senti Biosciences, Inc. announced plans for a holding company reorganization, which would convert existing common stock into equivalent shares of a new parent entity, Senti Biosciences Holdings, Inc., expected to be effective by April 16, 2026.
Key takeaways
The company plans a holding company reorganization via a tax-free merger into a subsidiary of Senti Biosciences Holdings, Inc.
Each share of existing common stock will convert into an equivalent share of the new holding company's common stock.
The reorganization is planned to be effective by April 16, 2026, but may be delayed or not implemented.
Stockholders will not recognize gain or loss for U.S. federal income tax purposes upon conversion of their shares.
Following the reorganization, the new holding company's common stock will continue trading on Nasdaq under the symbol 'SNTI' with a new CUSIP number.
The new holding company will have the same directors, executive officers, assets, and operations as the current company.